Financial PerformanceEBITDA rose 37% year-over-year, significantly ahead of both the company's and consensus estimates, indicating impressive financial performance.
Growth StrategyBTSG launched 5 new drugs in the third quarter and expects more launches over the next 12-18 months, indicating a strong growth strategy.
Revenue GrowthThe company raised its 2025 guidance for revenue growth, driven by significant growth across both Pharmacy Solutions and Provider Services.